# A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

> **NCT06717698** · PHASE2 · RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 465 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** NNC0519-0130
- **DRUG:** Placebo
- **DRUG:** Semaglutide

## Key facts

- **NCT ID:** NCT06717698
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-02
- **Primary completion:** 2026-09-01
- **Final completion:** 2026-09-17
- **Target enrollment:** 465 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06717698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06717698, "A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06717698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*